Dr. Michael Y. Sy, M.D.
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- University of California, Irvine, California College of Medicine (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 164
Licensed in California since 2013, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: University of California, Irvine, California College of Medicine
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
CA license A124536 (first issued 2013; current) - General Acute Care Hospital
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uci Health-Orange Orange, CA
Medical groups
- Regents of the University of Claifornia Univ Neursciences (74 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 164
- Services billed
- 456
- Patients’ average age
- 67
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 149 | 92 |
| Established patient office or other outpatient visit, 30-39 minutes | 42 | 33 |
| New patient office or other outpatient visit, 60-74 minutes | 15 | 15 |
| Established patient office or other outpatient visit, 20-29 minutes | 13 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Baclofen Other prescribers in Irvine, CA | 103 |
| Soliris (eculizumab) | 58 |
| Kesimpta Pen (ofatumumab) | 56 |
| Gabapentin Other prescribers in Irvine, CA | 54 |
| Copaxone (glatiramer acetate) | 53 |
| Glatiramer Acetate | 47 |
| Tizanidine Hcl Other prescribers in Irvine, CA | 46 |
| Enspryng (satralizumab-mwge) | 43 |
| Tamsulosin Hcl Other prescribers in Irvine, CA | 31 |
| Levetiracetam Other prescribers in Irvine, CA | 27 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 96 payments worth $69,130 in total to this clinician.
| Alexion Pharmaceuticals, Inc. | $46,742 |
|---|---|
| Genentech USA, Inc. | $8,574 |
| Amgen Inc. | $5,882 |
| UCB, Inc. | $4,400 |
| Novartis Pharmaceuticals Corporation | $2,843 |
| Tg Therapeutics, Inc. | $231 |
| Biogen, Inc. | $150 |
| Vanda Pharmaceuticals Inc. | $137 |
| Compensation for services other than consulting (speaking, faculty) | $39,760 |
|---|---|
| Consulting Fee | $21,680 |
| Travel and Lodging | $5,134 |
| Food and Beverage | $2,496 |
| Education | $60.50 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Alexion Pharmaceuticals, Inc. Apr 10, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $7,100 |
| Genentech USA, Inc. Oct 4, 2025 | Consulting Fee | $6,525 |
| Alexion Pharmaceuticals, Inc. Jul 2, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $5,680 |
| Alexion Pharmaceuticals, Inc. Feb 14, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $5,680 |
| Alexion Pharmaceuticals, Inc. Aug 27, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $5,680 |
| Amgen Inc. Apr 15, 2025 | Consulting Fee UPLIZNA · Inflammation/Rare Disease | $4,950 |
| UCB, Inc. Dec 24, 2025 | Consulting Fee | $4,400 |
| Alexion Pharmaceuticals, Inc. May 22, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $4,260 |
| Alexion Pharmaceuticals, Inc. Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $3,550 |
| Alexion Pharmaceuticals, Inc. May 1, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $3,550 |
All 43 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| UCB, Inc. Dec 24, 2025 | Consulting Fee | $4,400 |
| Genentech USA, Inc. Dec 9, 2025 | Consulting Fee | $825 |
| Alexion Pharmaceuticals, Inc. Oct 30, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $2,130 |
| Genentech USA, Inc. Oct 4, 2025 | Consulting Fee | $6,525 |
| Genentech USA, Inc. Oct 4, 2025 | Travel and Lodging travel to Denver, CO · in-kind | $371 |
| Genentech USA, Inc. Oct 4, 2025 | Travel and Lodging travel to Denver, CO · in-kind | $335 |
| Genentech USA, Inc. Oct 4, 2025 | Travel and Lodging travel to Denver, CO | $112 |
| Alexion Pharmaceuticals, Inc. Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $3,550 |
| Alexion Pharmaceuticals, Inc. Aug 27, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $5,680 |
| Alexion Pharmaceuticals, Inc. Aug 20, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Sacramento, CA | $35.98 |
| Alexion Pharmaceuticals, Inc. Aug 20, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Santa Ana, CA | $30.00 |
| Alexion Pharmaceuticals, Inc. Aug 19, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Sacramento, CA · in-kind Company’s descriptionSpeaker Expenses | $384 |
| Alexion Pharmaceuticals, Inc. Aug 19, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Sacramento, CA · in-kind Company’s descriptionSpeaker Expenses | $217 |
| Alexion Pharmaceuticals, Inc. Aug 19, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Sacramento, CA | $41.92 |
| Alexion Pharmaceuticals, Inc. Aug 19, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Sacramento, CA | $23.94 |
| Alexion Pharmaceuticals, Inc. Jul 2, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $5,680 |
| Alexion Pharmaceuticals, Inc. Jun 26, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $2,130 |
| Novartis Pharmaceuticals Corporation Jun 13, 2025 | Consulting Fee KESIMPTA · Neurology | $2,700 |
| Alexion Pharmaceuticals, Inc. Jun 7, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Irvine, CA | $97.88 |
| Alexion Pharmaceuticals, Inc. Jun 7, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to El Paso, TX | $53.96 |
| Alexion Pharmaceuticals, Inc. Jun 6, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to El Paso, TX · in-kind Company’s descriptionSpeaker Expenses | $304 |
| Alexion Pharmaceuticals, Inc. Jun 6, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Los Angeles, CA | $107 |
| Alexion Pharmaceuticals, Inc. Jun 6, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to El Paso, TX | $42.01 |
| Alexion Pharmaceuticals, Inc. May 23, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to El Paso, TX · in-kind Company’s descriptionSpeaker Expenses | $562 |
| Biogen, Inc. May 23, 2025 | Consulting Fee TYSABRI · Neurology | $150 |
| Alexion Pharmaceuticals, Inc. May 22, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $4,260 |
| Alexion Pharmaceuticals, Inc. May 14, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to San Diego, CA · in-kind Company’s descriptionSpeaker Expenses | $424 |
| Alexion Pharmaceuticals, Inc. May 13, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to San Diego, CA | $105 |
| Alexion Pharmaceuticals, Inc. May 13, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to San Diego, CA | $42.00 |
| Alexion Pharmaceuticals, Inc. May 12, 2025 | Consulting Fee | $2,130 |
| Alexion Pharmaceuticals, Inc. May 1, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $3,550 |
| Alexion Pharmaceuticals, Inc. Apr 22, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Pomona, CA | $42.00 |
| Amgen Inc. Apr 15, 2025 | Consulting Fee UPLIZNA · Inflammation/Rare Disease | $4,950 |
| Alexion Pharmaceuticals, Inc. Apr 10, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $7,100 |
| Amgen Inc. Apr 4, 2025 | Travel and Lodging UPLIZNA · Inflammation/Rare Disease · travel to SAN DIEGO, CA · in-kind | $393 |
| Alexion Pharmaceuticals, Inc. Mar 21, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Boston, MA · in-kind Company’s descriptionSpeaker Expenses | $633 |
| Alexion Pharmaceuticals, Inc. Mar 21, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Boston, MA · in-kind Company’s descriptionSpeaker Expenses | $255 |
| Alexion Pharmaceuticals, Inc. Mar 21, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Santa Ana, CA | $25.92 |
| Amgen Inc. Mar 17, 2025 | Education UPLIZNA · Inflammation/Rare Disease · in-kind | $60.50 |
| Alexion Pharmaceuticals, Inc. Feb 14, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $5,680 |
| Alexion Pharmaceuticals, Inc. Jan 31, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Phoenix, AZ · in-kind Company’s descriptionSpeaker Expenses | $435 |
| Alexion Pharmaceuticals, Inc. Jan 31, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Phoenix, AZ | $30.85 |
| Alexion Pharmaceuticals, Inc. Jan 31, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Santa Ana, CA | $29.73 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 7 companies. The companies reported $701,521 in research payments for these studies, mostly to the institutions running them.
- (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab
Tg Therapeutics, Inc. - Satralizumab in MOG AD
Genentech, Inc. - Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Genzyme Corporation · Active, not recruiting · NCT06141473 - A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After …
Novartis Pharmaceuticals Corporation - Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Genzyme Corporation · Active, not recruiting · NCT06141486 - Ocrelizumab PPMS High Dose Study
Genentech, Inc. - A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Autoimmune Neuro…
E.r. Squibb & Sons, L.l.c. - Evaluation of Fenebrutinib in RMS patients
Genentech, Inc. - A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, F…
Novartis Pharmaceuticals Corporation - Satralizumab in NMOSD patients 100kg
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.